AU2007290386A1 - Novel compositions and methods for treatment of diseases related to activated lymphocytes - Google Patents

Novel compositions and methods for treatment of diseases related to activated lymphocytes Download PDF

Info

Publication number
AU2007290386A1
AU2007290386A1 AU2007290386A AU2007290386A AU2007290386A1 AU 2007290386 A1 AU2007290386 A1 AU 2007290386A1 AU 2007290386 A AU2007290386 A AU 2007290386A AU 2007290386 A AU2007290386 A AU 2007290386A AU 2007290386 A1 AU2007290386 A1 AU 2007290386A1
Authority
AU
Australia
Prior art keywords
ici
compound
cell
serotonin
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007290386A
Other languages
English (en)
Other versions
AU2007290386A2 (en
Inventor
Clayton Buck
Gary Olson
Stephen Roth
Christopher Self
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corridor Pharmaceuticals Inc
Original Assignee
Immune Control Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Control Inc filed Critical Immune Control Inc
Publication of AU2007290386A1 publication Critical patent/AU2007290386A1/en
Publication of AU2007290386A2 publication Critical patent/AU2007290386A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/26—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom without other substituents attached to the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B21/00—Thiazine dyes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AU2007290386A 2006-09-01 2007-08-30 Novel compositions and methods for treatment of diseases related to activated lymphocytes Abandoned AU2007290386A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84177106P 2006-09-01 2006-09-01
US60/841,771 2006-09-01
PCT/US2007/019150 WO2008027521A1 (en) 2006-09-01 2007-08-30 Novel compositions and methods for treatment of diseases related to activated lymphocytes

Publications (2)

Publication Number Publication Date
AU2007290386A1 true AU2007290386A1 (en) 2008-03-06
AU2007290386A2 AU2007290386A2 (en) 2010-06-03

Family

ID=39136245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007290386A Abandoned AU2007290386A1 (en) 2006-09-01 2007-08-30 Novel compositions and methods for treatment of diseases related to activated lymphocytes

Country Status (6)

Country Link
US (2) US7923445B2 (cg-RX-API-DMAC7.html)
EP (1) EP2061788A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010502621A (cg-RX-API-DMAC7.html)
AU (1) AU2007290386A1 (cg-RX-API-DMAC7.html)
CA (1) CA2662215A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008027521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035161A1 (en) * 2006-09-01 2012-02-09 Corridor Pharmaceuticals, Inc. Novel Compositions and Methods of Treating Diseases Using the Same
US20100035858A1 (en) * 2008-07-18 2010-02-11 Immune Control, Inc. Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor
US20100130457A1 (en) * 2008-11-14 2010-05-27 Immune Control, Inc. Phenothiazine Derivatives for Treatment of Asthma
EP2246349A1 (en) * 2009-04-20 2010-11-03 BKG Pharma ApS Treatment of infectious diseases
WO2010124100A1 (en) * 2009-04-22 2010-10-28 Immune Control, Inc. Novel selective 5-ht4 receptor antagonists
JP6069321B2 (ja) * 2011-08-02 2017-02-01 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハーＨｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ Ｕｎｄ Ｕｍｗｅｌｔ Ｇｍｂｈ フェノチアジン誘導体によるｍａｌｔ１プロテアーゼの選択的阻害
US10639382B2 (en) 2017-04-13 2020-05-05 National Guard Health Affairs Method for treating leukemia
US11542290B2 (en) 2018-04-06 2023-01-03 Camp4 Therapeutics Corporation Phenothiazine derivatives and uses thereof
EP3574920A1 (en) * 2018-05-31 2019-12-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nupr1 inhibition for treating cancer
WO2021105391A1 (en) * 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination comprising nupr1 inhibitors to treat cancer
WO2021105384A1 (en) * 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
CN116202939A (zh) * 2023-01-16 2023-06-02 中国科学技术大学 一种多发性硬化（ms）残疾程度的新型评价方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
US2687414A (en) * 1948-11-26 1954-08-24 Searle & Co Method for producing aromatic aminoalkyl amines
NL106170C (cg-RX-API-DMAC7.html) * 1955-12-23
GB824598A (en) * 1957-02-14 1959-12-02 Rhone Poulenc Sa Improvements in or relating to new phenthiazine derivatives and processes for their preparation
US3058979A (en) * 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
GB903725A (en) * 1957-11-02 1962-08-15 Knoll Ag Phenthiazine derivatives
NL222355A (cg-RX-API-DMAC7.html) * 1957-11-05
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
US3595989A (en) * 1970-02-25 1971-07-27 Philco Ford Corp Dc-coupled chroma processing integrated circuit
GB1382769A (en) * 1973-02-19 1975-02-05 Esteve Labor Dr 3-substituted phenothiazine derivatives
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
US6333322B1 (en) * 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
US6800618B2 (en) * 2001-05-07 2004-10-05 The United States Of America As Represented By The Secretary Of The Army Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof
WO2002089810A1 (en) * 2001-05-07 2002-11-14 United States Army Medical Research And Materiel Command Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof
US20030229082A1 (en) 2002-01-16 2003-12-11 The Regents Of The University Of California Inhibition of RNA function
US6664266B2 (en) 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
CA2488708A1 (en) * 2002-06-17 2003-12-24 Philadelphia Health And Education Corporation (D/B/A Mcp Hahnemann University) Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms

Also Published As

Publication number Publication date
WO2008027521A1 (en) 2008-03-06
EP2061788A4 (en) 2010-10-06
JP2010502621A (ja) 2010-01-28
US7923445B2 (en) 2011-04-12
US20080125415A1 (en) 2008-05-29
EP2061788A1 (en) 2009-05-27
US7981885B2 (en) 2011-07-19
US20080132697A1 (en) 2008-06-05
AU2007290386A2 (en) 2010-06-03
CA2662215A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
US7981885B2 (en) Compositions for treatment of diseases related to activated lymphocytes
US5478934A (en) Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands
US6656943B2 (en) 1-phenyl-4-benzlpiperazines: dopamine receptor subtype specific ligands
JP2983296B2 (ja) 新規なｎ−アミノアルキルフルオレンカルボキサミド；新規な種類のドーパミンリセプタ亜型特異性リガンド
JP6630374B2 (ja) τリン酸化を阻害する方法
RS63603B1 (sr) Sredstva za indukciju apoptoze
JPWO2009022731A1 (ja) Ｐ２ｘ４受容体拮抗剤
HUT72443A (en) Heterocyclic compounds and their preparation and use
FI71558B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla n-(4-indolylpiperidino-alkyl) benzimidazoloner
WO2000055154A1 (de) Abgewandelte aminosäureamide als cgrp antagoniste
CN103717069A (zh) 有机化合物
US6245768B1 (en) 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
KR100417506B1 (ko) 항우울 치료를 위한 5ｈｔ1 길항제
JP6542236B2 (ja) 有機化合物
US20100099673A1 (en) Decahydroquinoline analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20090275557A1 (en) Novel Composition for Treatment of Diseases Related to Activated Lymphocytes
US12304914B2 (en) Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as IRAK4 inhibitors
US20120035161A1 (en) Novel Compositions and Methods of Treating Diseases Using the Same
WO2010124100A1 (en) Novel selective 5-ht4 receptor antagonists
US20100035858A1 (en) Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor
JP2918002B2 (ja) アミノメチル アリール化合物；ドーパミンレセプター亜型選択性リガンド
JPH037229A (ja) 脳神経機能改善剤
US12391702B2 (en) Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
KR100212435B1 (ko) 1,4-벤조디아제핀-2,5-디온 유도체 및 약학적으로 허용되는 그의 염
JPS62221683A (ja) 芳香族ω−アルキルイミノテトラヒドロ−６Ｈ−１，３−チアジン−６−オン誘導体

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 17 MAY 2010

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period